Literature DB >> 9692772

Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle.

A Choppin1, R M Eglen, S S Hegde.   

Abstract

1. The pharmacological characteristics of muscarinic receptors in the rabbit iris sphincter muscle were studied and compared to M3 receptors in rabbit urinary bladder smooth muscle. 2. (+/-)-Cis-dioxolane induced concentration-dependent contractions of the iris sphincter muscle (pEC50 = 6.41+/-0.10, Emax = 181+/-17 mg, n = 38) and urinary bladder smooth muscle (pEC50 = 6.97+/-0.04, Emax = 4.28+/-0.25 g, n = 54). These contractions were competitively antagonized by a range of muscarinic receptor antagonists (pK(B) values are given for the iris sphincter muscle and the bladder smooth muscle, respectively): atropine (9.30+/-0.07 and 9.40+/-0.04), AQ-RA 741 (6.35+/-0.04 and 6.88+/-0.03), darifenacin (9.56+/-0.05 and 9.12+/-0.05), methoctramine (5.75+/-0.07 and 5.81+/-0.06), oxybutynin (8.10+/-0.09 and 8.59+/-0.06), pirenzepine (6.79+/-0.05 and 6.89+/-0.04), secoverine (7.54+/-0.05 and 7.66+/-0.05), p-F-HHSiD (7.55+/-0.09 and 7.50+/-0.05) and zamifenacin (8.69+/-0.10 and 8.36+/-0.06). A significant correlation between the pK(B) values in the bladder and the pK(B) values in the iris was obtained. 3. In both tissues, the pK(B) values correlated most favorably with pKi values for these compounds at human recombinant muscarinic m3 receptors. A reasonable correlation was also noted at human recombinant muscarinic m5 receptors given the poor discriminative ability of ligands between m3 and m5 receptors. 4. Overall, the data from this study suggest that the muscarinic receptors mediating contraction of the rabbit iris sphincter muscle and urinary bladder smooth muscle are similar and equate most closely with the pharmacologically-defined muscarinic M3 receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692772      PMCID: PMC1565469          DOI: 10.1038/sj.bjp.0701920

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells.

Authors:  N Watson; D V Daniels; A P Ford; R M Eglen; S S Hegde
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 2.  The muscarinic M(5) receptor: a silent or emerging subtype?

Authors:  R M Eglen; S R Nahorski
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  The role of M(2)-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro.

Authors:  T Yamanishi; C R Chapple; K Yasuda; R Chess-Williams
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  M(3) muscarinic receptors mediate contraction of human urinary bladder.

Authors:  Charlotte Fetscher; Marina Fleichman; Martina Schmidt; Susanne Krege; Martin C Michel
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

5.  Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains.

Authors:  A Choppin
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

6.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

7.  An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude.

Authors:  Mehmet Ali Sekeroglu; Emre Hekimoglu; Mustafa Alpaslan Anayol; Yasemin Tasci; Ismail Dolen
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

8.  AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.

Authors:  S Sinha; S Gupta; S Malhotra; N S Krishna; A V Meru; V Babu; V Bansal; M Garg; N Kumar; A Chugh; A Ray
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

9.  Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats.

Authors:  Helena-F Wrzos; Tarun Tandon; Ann Ouyang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 10.  A benefit-risk assessment of extended-release oxybutynin.

Authors:  Martin C Michel
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.